HC Wainwright Reiterates Buy Rating for electroCore (NASDAQ:ECOR)

Posted by Doug Wharley on Mar 13th, 2025

electroCore (NASDAQ:ECOR – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They currently have a $25.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 92.31% from the company’s current price.

electroCore Trading Down 1.4 %

Shares of NASDAQ ECOR opened at $13.00 on Thursday. The firm has a market cap of $86.53 million, a price-to-earnings ratio of -7.10 and a beta of 0.24. The stock has a fifty day simple moving average of $16.16 and a two-hundred day simple moving average of $12.26. electroCore has a 1-year low of $5.32 and a 1-year high of $19.49.

Institutional Investors Weigh In On electroCore

Several institutional investors have recently added to or reduced their stakes in ECOR. Jane Street Group LLC purchased a new position in shares of electroCore in the fourth quarter worth about $278,000. Marshall Wace LLP purchased a new position in electroCore in the 4th quarter valued at approximately $438,000. NewEdge Advisors LLC purchased a new position in electroCore in the 4th quarter valued at approximately $274,000. Renaissance Technologies LLC raised its holdings in electroCore by 80.6% during the 4th quarter. Renaissance Technologies LLC now owns 131,786 shares of the company’s stock valued at $2,136,000 after acquiring an additional 58,800 shares during the period. Finally, DnB Asset Management AS purchased a new stake in shares of electroCore during the fourth quarter worth $180,000. 26.74% of the stock is owned by hedge funds and other institutional investors.

electroCore Company Profile

(Get Free Report)

electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.